Pangaea Logistics Solutions Ltd. (PANL) earnings date, results and what the price requires
Nasdaq · SEC CIK 0001606909 · SEC filings checked Oct 18, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 10, 2026 | $187.1M | $10.2M | $0.16 | Filing |
| Mar 31, 2026 | May 11, 2026 | $170.6M | $13.3M | $0.21 | Filing |
| Dec 31, 2025 | Mar 11, 2026 | $183.9M | $11.9M | $0.18 | Filing |
| Sep 30, 2025 | Nov 6, 2025 | $168.7M | $12.2M | $0.19 | Filing |
| Jun 30, 2025 | Aug 7, 2025 | $156.7M | $-2.7M | $-0.04 | Filing |
| Mar 31, 2025 | May 12, 2025 | $122.8M | $-2.0M | $-0.03 | Filing |
| Dec 31, 2024 | Mar 13, 2025 | $147.2M | $8.4M | $0.19 | Filing |
| Sep 30, 2024 | Nov 13, 2024 | $153.1M | $5.1M | $0.11 | Filing |
What would Pangaea Logistics Solutions Ltd. have to report for its valuation to change?
At $7.87, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about -1.9% a year, to $0.67. On that path the next quarter needs diluted EPS near $0.19, against $0.19 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | -1.9% | -1.9% |
| EPS needed in final year | $0.67 | $0.67 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. PANL goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.